This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Entasis Therapeutics Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

90.2%

Borç/özkaynak oranı

US$15.01m

Borç

Faiz karşılama oranı	n/a
Nakit	US$33.55m
Eşitlik	US$16.65m
Toplam yükümlülükler	US$27.44m
Toplam varlıklar	US$44.09m

Son finansal sağlık güncellemeleri

Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?

Dec 16

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Aug 19

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Dec 01

Recent updates

Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?

Dec 16

Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products

Nov 17

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Aug 19

Entasis Therapeutics shares rise after lining up ETX0462 poster presentation

Jun 18

What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?

Feb 17

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Dec 01

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ETTX 'nin kısa vadeli varlıkları ( $39.9M ) kısa vadeli yükümlülüklerini ( $24.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: ETTX şirketinin kısa vadeli varlıkları ( $39.9M ) uzun vadeli yükümlülüklerini ( $3.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ETTX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: ETTX şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ETTX şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: ETTX un, serbest nakit akışı her yıl % 10.6 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

This company has been acquired

Entasis Therapeutics Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Recent updates

Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from NASDAQ Composite Index

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell Microcap Value Index

Entasis Therapeutics Holdings Inc. Presents Data Highlights from Phase 3 Attack Trial At 2022 American Thoracic Society Annual Conference

Price target decreased to US$2.00

Forecast to breakeven in 2024

Price target decreased to US$2.65

Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference

Entasis Therapeutics Holdings Inc. Announces Executive Changes

Entasis Therapeutics Holdings Inc. announced that it has received $15 million in funding from Innoviva Strategic Opportunities LLC

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?

Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Entasis Therapeutics Holdings Inc. Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens

Entasis Therapeutics shares rise after lining up ETX0462 poster presentation

Entasis Therapeutics Holdings Inc. announced that it has received $20 million in funding from Innoviva Strategic Opportunities LLC

Price target decreased to US$6.00

Consensus forecasts updated

Entasis Therapeutics Holdings Inc. announced that it expects to receive $20 million in funding from Innoviva Strategic Opportunities LLC

What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?

Entasis Therapeutics Holdings Inc. Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S

New 90-day high: US$2.95

New 90-day high: US$2.72

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Earnings miss expectations

New 90-day low: US$1.83

New 90-day low: US$2.25

Entasis Therapeutics Holdings Inc. announced that it expects to receive $24.999999 million in funding from Innoviva, Inc., Armistice Capital LLC

Entasis Therapeutics Holdings Inc. announced that it expects to receive $28.108125 million in funding from Innoviva, Inc., and other investors

New 90-day low - US$2.51

Earnings released

New 90-day high - US$3.77

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin